Ology Bioservices Enters Phase 1 Clinical Trial for Anti-COVID-19 Monoclonal Antibodies December 17, 2020 03:00 PM Eastern Standard Time ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices Inc. (Ology Bio), a biologics contract development and manufacturing organization (CDMO), announced [...]
Ology Bioservices, Inc. Strategic Partner for Bioanalytical Testing Pharma Tech Outlook - November 23, 2020 Ology Bioservices, Inc. (Ology Bio) is a US based, biologics-focused, full-service contract development and manufacturing organization (CDMO). The company has [...]
Ology Bioservices Awarded $37 Million by Department of Defense for Advanced Development of Anti-COVID-19 Monoclonal Antibody Cocktail November 23, 2020 08:00 AM Eastern Standard Time ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices Inc. (Ology Bio), a biologics contract [...]
Ology Bioservices Named 2020 Company of the Year by BioFlorida October 30, 2020 01:12 PM Eastern Daylight Time ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices Inc. (Ology Bio), a biologics contract development and manufacturing organization (CDMO), announced today [...]
Department of Defense Awards Ology Bioservices Contract to Manufacture and Test Novel Live Attenuated Tularemia Vaccine Candidate October 27, 2020 08:30 AM Eastern Daylight Time ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices Inc. (Ology Bio), a biologics contract [...]
MasterControl Recognizes Customers’ Achievements The first annual Masters of Excellence Awards highlights customer success October 22, 2020 08:00 ET | Source: MasterControl Inc. SALT LAKE CITY, Oct. 22, 2020 (GLOBE NEWSWIRE) -- MasterControl, a provider of software solutions [...]
Nanotherapeutics, Inc., an integrated biopharmaceutical company with a focus on advanced development and manufacturing, announced today that it has secured a $28.5 million debt financing from White Oak Global Advisors, LLC. The funds will support the completion of the Company’s 180,000 sq. ft. flexible biologics manufacturing facility located in Alachua.
The NANO-ADM (Advanced Development and Manufacturing) facility, as it is known, will expand Nanotherapeutics’ core competencies in the development and cGMP manufacture of preclinical and clinical stage biopharmaceutical products. The Company provides a full range of drug development services and intends to further capitalize on its capabilities through partnerships with government and established companies, as well as continuing to fund the development of its internal pipeline.
Tomic MT, Espinoza Y, Martinez Z, et al. Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model. Toxins 2019, 11(4), 208; https://doi.org/10.3390/toxins11040208.
Barrett PN, Terpening SJ, Snow D, Cobb RR, Kistner O. Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases. Expert Review of Vaccines. 2017;16(9):883-894.
These are unprecedented times as we respond to avoid the spread of COVID-19, a novel coronavirus that has challenged our routine life. First and foremost, all of us at Ology Bioservices Inc. hope you and your family members are well, healthy, and safe from harm’s way.
Below are some of the steps we are taking to protect our staff, our operations, and importantly all ongoing projects at Ology Bioservices during this time. Our goal is to be prepared to continue serving our clients during this time of uncertainty. In order to protect our employees and facility, and to keep projects moving forward, we have implemented the following activities:
Increased our supplies of commonly used laboratory and manufacturing materials, well in advance of the declaration of a pandemic.
Creation of a New Visitor Policy at all locations to further protect the facilities and employees.
Permitting only service personnel, vendors, and contractors on site for highly specialized activities.
Donning face masks and sanitizing hands for all persons entering our facilities.
Requiring social distancing for all personnel.
Requiring health screening for all persons entering our facilities.
Expanded our IT structure to allow employees with the ability to “work from home” wherever possible.
Cancelled business travel for all employees of Ology Bioservices.
Cancelled or rescheduled larger meetings or gatherings.
There will be no disruption in communicating with Ology Bioservices personnel, and our offices will remain open. However, the limited number of personnel physically at our locations will mainly consist of those involved in supporting the process development and manufacturing of our customer’s biological products. Be assured that you will be able to reach all employees through their direct phone lines and email regardless of their location during this crisis.
The entire leadership team at Ology Bioservices remain committed to the health and safety of our employees, as well as committed to the customers we serve. This nation has a history of strength and resilience, and I am certain that together we will successfully navigate these challenges.